Company news

Celcuity Inc. news in 2025

Celcuity Inc.'s news releases, calls and decks from 2025, newest first.

View company

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

December 10, 2025

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

November 25, 2025

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

November 25, 2025

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

November 16, 2025

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 11, 2025

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

November 4, 2025

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

November 3, 2025

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

October 17, 2025

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

October 17, 2025

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

October 17, 2025

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

September 21, 2025

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

September 8, 2025

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program

August 26, 2025

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

August 6, 2025

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

July 29, 2025

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

July 28, 2025

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

July 27, 2025

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

July 27, 2025

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

July 24, 2025

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

July 23, 2025

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

July 13, 2025

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

June 29, 2025

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 20, 2025

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 6, 2025

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

March 31, 2025

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 30, 2025

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

March 24, 2025

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

February 24, 2025

Calls in 2025

Decks in 2025